OQL011, for cancer therapy induced skin toxicity, demonstrated a tolerable safety and acceptable efficacy profile, according to topline results of part 1 of the phase 2 NOVA-II trial reported by OnQuality Pharmaceuticals. OQL011 is an ointment designed to treat hand-foot skin reaction (HFSR) which is a common adverse event of tyrosine kinase inhibitors, including VEGF […]

In phase 1 and 2 studies (NCT04524351), respectively, people with early Alzheimer disease (AD) and early Parkinson disease (PD) who were treated with posiphen (ANVS401; Annovis, Berwyn, PA) had statistically significant clinical improvements. Changes in biomarkers of neurodegeneration and neuroinflammation were also observed. Posiphen is an orally administered translational inhibitor of neurotoxic proteins that form […]

Biotricity (BTCY) is a medical technology company that develops solutions to aid in chronic diseases prevention and management. Dr. Waqaas Al-Siddiq, Chairman, CEO, and Founder of Biotricity, gives an overview of the company and discusses the stock. He also talks about Bioflux which is a mobile cardiac telemetry device and BTCY’s lead product. Tune into […]